Hester Biosciences Limited (HESTERBIO) - Net Assets

Latest as of September 2025: Rs3.51 Billion INR ≈ $37.96 Million USD

Based on the latest financial reports, Hester Biosciences Limited (HESTERBIO) has net assets worth Rs3.51 Billion INR (≈ $37.96 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs6.75 Billion ≈ $73.02 Million USD) and total liabilities (Rs3.24 Billion ≈ $35.06 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check HESTERBIO financial resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs3.51 Billion
% of Total Assets	51.99%
Annual Growth Rate	18.19%
5-Year Change	38.44%
10-Year Change	211.65%
Growth Volatility	20.99

Hester Biosciences Limited - Net Assets Trend (2006–2025)

This chart illustrates how Hester Biosciences Limited's net assets have evolved over time, based on quarterly financial data. Also explore Hester Biosciences Limited (HESTERBIO) total assets for the complete picture of this company's asset base.

Annual Net Assets for Hester Biosciences Limited (2006–2025)

The table below shows the annual net assets of Hester Biosciences Limited from 2006 to 2025. For live valuation and market cap data, see how much is Hester Biosciences Limited worth.

Year	Net Assets	Change
2025-03-31	Rs3.27 Billion ≈ $35.33 Million	+7.85%
2024-03-31	Rs3.03 Billion ≈ $32.75 Million	+3.59%
2023-03-31	Rs2.92 Billion ≈ $31.62 Million	+9.35%
2022-03-31	Rs2.67 Billion ≈ $28.92 Million	+13.32%
2021-03-31	Rs2.36 Billion ≈ $25.52 Million	+14.27%
2020-03-31	Rs2.06 Billion ≈ $22.33 Million	+13.99%
2019-03-31	Rs1.81 Billion ≈ $19.59 Million	+24.93%
2018-03-31	Rs1.45 Billion ≈ $15.68 Million	+16.76%
2017-03-31	Rs1.24 Billion ≈ $13.43 Million	+18.49%
2016-03-31	Rs1.05 Billion ≈ $11.34 Million	+24.99%
2015-03-31	Rs838.58 Million ≈ $9.07 Million	+9.92%
2014-03-31	Rs762.88 Million ≈ $8.25 Million	+11.38%
2013-03-31	Rs684.95 Million ≈ $7.41 Million	+12.18%
2012-03-31	Rs610.60 Million ≈ $6.60 Million	+27.25%
2011-03-31	Rs479.85 Million ≈ $5.19 Million	+17.43%
2010-03-31	Rs408.64 Million ≈ $4.42 Million	+11.51%
2009-03-31	Rs366.47 Million ≈ $3.96 Million	+9.49%
2008-03-31	Rs334.69 Million ≈ $3.62 Million	+19.76%
2007-03-31	Rs279.47 Million ≈ $3.02 Million	+104.77%
2006-03-31	Rs136.48 Million ≈ $1.48 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Hester Biosciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 237086000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs2.37 Billion	75.44%
Common Stock	Rs85.07 Million	2.71%
Other Comprehensive Income	Rs511.55 Million	16.28%
Other Components	Rs175.07 Million	5.57%
Total Equity	Rs3.14 Billion	100.00%

Hester Biosciences Limited Competitors by Market Cap

The table below lists competitors of Hester Biosciences Limited ranked by their market capitalization.

Company	Market Cap
Arrowmark Financial Corp NASDAQ:BANX	$150.43 Million
Westwood Holdings Group Inc NYSE:WHG	$150.44 Million
Naturhouse Health SA MC:NTH	$150.47 Million
Lotus Resources Ltd AU:LOT	$150.50 Million
PT MNC Energy Investments Tbk JK:IATA	$150.28 Million
Wanhwa Enterprise Co TW:2701	$150.27 Million
Reit Azorim HF Living Ltd TA:AZRT	$150.21 Million
Dune Acquisition Corporation II Class A Ordinary Shares NASDAQ:IPOD	$150.19 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hester Biosciences Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 2,917,930,000 to 3,142,550,000, a change of 224,620,000 (7.7%).
Net income of 274,880,000 contributed positively to equity growth.
Dividend payments of 51,680,000 reduced retained earnings.
Other comprehensive income increased equity by 4,649,999.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs274.88 Million	+8.75%
Dividends Paid	Rs51.68 Million	-1.64%
Other Comprehensive Income	Rs4.65 Million	+0.15%
Other Changes	Rs-3.23 Million	-0.1%
Total Change	Rs-	7.70%

Book Value vs Market Value Analysis

This analysis compares Hester Biosciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.22x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 69.83x to 4.22x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-03-31	Rs23.40	Rs1634.20	x
2007-03-31	Rs40.31	Rs1634.20	x
2008-03-31	Rs42.98	Rs1634.20	x
2009-03-31	Rs47.06	Rs1634.20	x
2010-03-31	Rs52.48	Rs1634.20	x
2011-03-31	Rs61.62	Rs1634.20	x
2012-03-31	Rs70.60	Rs1634.20	x
2013-03-31	Rs93.38	Rs1634.20	x
2014-03-31	Rs88.18	Rs1634.20	x
2015-03-31	Rs96.86	Rs1634.20	x
2016-03-31	Rs118.39	Rs1634.20	x
2017-03-31	Rs140.61	Rs1634.20	x
2018-03-31	Rs165.32	Rs1634.20	x
2019-03-31	Rs208.61	Rs1634.20	x
2020-03-31	Rs236.36	Rs1634.20	x
2021-03-31	Rs268.38	Rs1634.20	x
2022-03-31	Rs305.62	Rs1634.20	x
2023-03-31	Rs343.70	Rs1634.20	x
2024-03-31	Rs343.01	Rs1634.20	x
2025-03-31	Rs387.44	Rs1634.20	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hester Biosciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 8.75%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 8.84%
• Asset Turnover: 0.48x
• Equity Multiplier: 2.08x
Recent ROE (8.75%) is below the historical average (15.94%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	32.57%	22.13%	0.89x	1.65x	Rs30.80 Million
2007	18.43%	23.60%	0.34x	2.28x	Rs23.57 Million
2008	21.04%	21.57%	0.48x	2.05x	Rs36.94 Million
2009	12.92%	15.70%	0.40x	2.03x	Rs10.72 Million
2010	14.76%	16.07%	0.46x	1.98x	Rs19.47 Million
2011	15.83%	18.10%	0.47x	1.86x	Rs27.97 Million
2012	12.73%	15.76%	0.51x	1.60x	Rs16.33 Million
2013	13.76%	14.22%	0.53x	1.84x	Rs25.29 Million
2014	12.60%	13.69%	0.49x	1.90x	Rs19.53 Million
2015	15.13%	13.75%	0.57x	1.94x	Rs42.26 Million
2016	18.75%	18.72%	0.55x	1.83x	Rs88.12 Million
2017	19.60%	19.05%	0.56x	1.82x	Rs114.87 Million
2018	18.22%	18.85%	0.56x	1.74x	Rs115.58 Million
2019	23.42%	23.34%	0.59x	1.69x	Rs238.21 Million
2020	14.51%	15.92%	0.48x	1.91x	Rs90.64 Million
2021	15.08%	16.06%	0.52x	1.80x	Rs115.99 Million
2022	15.12%	16.73%	0.42x	2.16x	Rs133.22 Million
2023	9.11%	10.01%	0.49x	1.87x	Rs-26.11 Million
2024	6.47%	6.20%	0.46x	2.27x	Rs-102.90 Million
2025	8.75%	8.84%	0.48x	2.08x	Rs-39.38 Million

Industry Comparison

This section compares Hester Biosciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $23,713,303,062
Average return on equity (ROE) among peers: 8.81%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Hester Biosciences Limited (HESTERBIO)	Rs3.51 Billion	32.57%	0.92x	$150.34 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$988.60 Million	6.59%	1.36x	$27.93 Million
Aarti Drugs Limited (AARTIDRUGS)	$6.52 Billion	21.67%	1.42x	$371.43 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$19.90 Billion	13.69%	0.46x	$725.68 Million
Abbott India Limited (ABBOTINDIA)	$36.99 Billion	32.48%	0.40x	$5.85 Billion
Ajanta Pharma Limited (AJANTPHARM)	$1.16 Billion	12.69%	1.32x	$3.81 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$6.25 Billion	-40.39%	3.91x	$906.19 Million
Alkem Laboratories Limited (ALKEM)	$88.47 Billion	18.60%	0.59x	$6.98 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.46 Billion	16.82%	0.29x	$178.52 Million
Alembic Pharmaceuticals Limited (APLLTD)	$51.90 Billion	11.24%	0.50x	$1.60 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$23.50 Billion	-5.26%	1.65x	$8.73 Billion

About Hester Biosciences Limited

NSE:HESTERBIO India Drug Manufacturers - Specialty & Generic

Market Cap

$150.34 Million

Rs13.90 Billion INR

Market Cap Rank

#17629 Global

#914 in India

Share Price

Rs1634.20

Change (1 day)

-1.29%

52-Week Range

Rs1259.10 - Rs2193.80

All Time High

Rs3204.96